Turnover: 976.6 million EUR (2022)
Country: France
Manufacturer of active pharmaceutical ingredients
Former division of Sanofi specializing in the manufacture of active ingredients, listed on the stock exchange since 2023
100% European production
News
Pharmaceuticals: Euroapi halts production at its Italian plant 15/03/2024
- Euroapi IPO: May 2022
- Production shutdown at Italian plant in Brindisi, due to quality control failures
- Brindisi production: 11 APIs, mainly anti-infectives/antibiotics
- Brindisi sales in 2023: 63 million euros, 43% with Sanofi
- Turnaround plan announced on February 28, 2024, after annual losses increased from 15 to 190 million euros
- Plant disposals: two at six European sites, including Brindisi and one in the UK
- Fall in Euroapi's market value: 70% since IPO
- Sanofi's plan: IPO of its family health division, Opella, planned for late 2024 at the earliest
> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)
Sector-GPT est la première IA dédiée aux informations sectorielles.